Verona Pharma plc (VRNA)

GB — Healthcare Sector
Peers: VTYX  IDYA  PTGX  SNDX  DAWN  XFOR  INZY  ABOS  MREO  TERN  AMLX  MLTX  MRTX  APLS  AKRO  MDGL  VKTX 

Automate Your Wheel Strategy on VRNA

With Tiblio's Option Bot, you can configure your own wheel strategy including VRNA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol VRNA
  • Rev/Share 0.1745
  • Book/Share 0.3335
  • PB 30.433
  • Debt/Equity 0.0094
  • CurrentRatio 8.8608
  • ROIC -0.3089

 

  • MktCap 6900285949.0
  • FreeCF/Share -0.1772
  • PFCF -57.3249
  • PE -42.0428
  • Debt/Assets 0.0041
  • DivYield 0
  • ROE -0.8989

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation VRNA TD Cowen -- Buy -- $100 April 28, 2025
Initiation VRNA Cantor Fitzgerald -- Overweight -- $80 April 21, 2025
Initiation VRNA ROTH MKM -- Buy -- $68 Jan. 10, 2025
Initiation VRNA Wells Fargo -- Overweight -- $50 Oct. 3, 2024

News

Verona Pharma Announces June 2025 Investor Conference Participation
VRNA
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025:

Read More
image for news Verona Pharma Announces June 2025 Investor Conference Participation
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025
VRNA
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population

Read More
image for news Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025
Silencing The Doubters: Verona Pharma Could Be Sitting On A Blockbuster
VRNA
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Positive

VRNA's COPD drug Ohtuvayre shows impressive Q1'25 net sales of $71.3M in just its third quarter of sales, all but confirming the blockbuster future of the drug. Ongoing R&D and trials, including a phase 3 trial in China that should readout in Q2'25, represent future clinical catalysts. A partnership in the UK or Europe is another potential near-term catalyst, although if the terms are not favorable, that could impact the performance of the stock.

Read More
image for news Silencing The Doubters: Verona Pharma Could Be Sitting On A Blockbuster
Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript
VRNA
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Neutral

Verona Pharma plc (NASDAQ:VRNA ) Q1 2025 Earnings Conference Call April 29, 2025 9:00 AM ET Company Participants Victoria Stewart - Senior Director, Investor Relations and Communications David Zaccardelli - President and CEO Mark Hahn - CFO Christopher Martin - CCO Tara Rheault - Chief Development Officer Kathleen Rickard - Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler Olivia Brayer - Cantor Fitzgerald Tara Bancroft - TD Cowen Tiago Fauth - Wells Fargo Thomas Shrader - BTIG Ram Selvaraju - HCW Sushila Hernandez - Van Lanschot Kempen Boobalan Pachaiyappan - ROTH Operator Welcome …

Read More
image for news Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript
Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
VRNA
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024)

Read More
image for news Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical
VRNA
Published: April 07, 2025 by: Seeking Alpha
Sentiment: Positive

Ohtuvayre's robust launch for COPD treatment exceeded expectations, with Q4 revenue of $36.6 million and FY24 revenue of $42.3 million, indicating strong market demand. Verona's financial health is solid with $399.757 million in cash, providing a cash runway into 2028, despite a net loss of $33.8 million in Q4. Verona is extending Ohtuvayre's life cycle through new formulations and fixed-dose combinations, aiming for cash flow break-even with a quarterly run rate near $300 million.

Read More
image for news Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical
Verona Pharma plc (VRNA) Q4 2024 Earnings Call Transcript
VRNA
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral

Verona Pharma plc (NASDAQ:VRNA ) Q4 2024 Earnings Conference Call February 27, 2024 9:00 AM ET Company Participants David Zaccardelli - President and CEO Mark Hahn - CFO Christopher Martin - CCO Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler Tiago Fauth - Wells Fargo Tom Shrader - BTIG Ram Selvaraju - HCW Joon Lee - Truist Boobalan Pachaiyappan - ROTH Operator Good morning ladies and gentlemen. Welcome to the Verona Pharma Fourth Quarter and Full Year 2024 Financial Results and Conference Call.

Read More
image for news Verona Pharma plc (VRNA) Q4 2024 Earnings Call Transcript
Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
VRNA
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

Ohtuvayre TM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024

Read More
image for news Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Verona Pharma Announces March 2025 Investor Conference Participation
VRNA
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025:

Read More
image for news Verona Pharma Announces March 2025 Investor Conference Participation
Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update
VRNA
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2024 on Thursday, February 27, 2025 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

Read More
image for news Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update
What Makes Verona Pharma (VRNA) a Good Fit for 'Trend Investing'
VRNA
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive

If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Read More
image for news What Makes Verona Pharma (VRNA) a Good Fit for 'Trend Investing'

About Verona Pharma plc (VRNA)

  • IPO Date 2017-04-28
  • Website https://www.veronapharma.com
  • Industry Biotechnology
  • CEO Dr. David S. Zaccardelli Pharm.D.
  • Employees 209

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.